Knowra Betamethasone Betamethasone Betamethasone is a potent synthetic glucocorticoid that reduces inflammation and immune activity. It is used in several formulations to treat skin, allergic, and autoimmune conditions and to accelerate fetal lung maturation.
Glucocorticoid receptor : A steroid-activated transcription factor that regulates genes involved in inflammation, metabolism, and stress responses. Betamethasone binds this receptor to suppress inflammatory signaling and alter immune-cell activity.
Atopic dermatitis : A chronic inflammatory skin disease marked by itchy, recurrent eczematous lesions. Topical betamethasone may be prescribed for flares when its potency is appropriate for the site and severity.
Hydrocortisone : The pharmaceutical form of cortisol, used as a glucocorticoid and, in some settings, mineralocorticoid replacement. Hydrocortisone is less potent than betamethasone and has different mineralocorticoid activity.
Hypothalamic–pituitary–adrenal axis : A hormonal feedback system linking the hypothalamus, pituitary gland, and adrenal glands to regulate stress responses. Systemic betamethasone can suppress this axis and reduce the body's own cortisol production.
Glucocorticoid potency : The relative strength of glucocorticoids in producing specified biological effects, such as anti-inflammatory activity. Potency helps explain why topical betamethasone requires careful selection by body site and condition.
Glucocorticoid : A class of steroid hormones and medicines that regulate metabolism and suppress inflammation and immune responses. Betamethasone is a synthetic member of this broader drug and hormone class.
Psoriasis : A chronic immune-mediated disease that produces sharply defined, often scaly plaques on the skin. Topical betamethasone can reduce inflammation and scaling in localized psoriasis.
Dexamethasone : A potent, long-acting synthetic glucocorticoid used to treat inflammation and other conditions. Dexamethasone resembles betamethasone in potency and duration but differs in chemical structure and clinical formulations.
Glucocorticoid-induced osteoporosis : Bone loss and fracture risk caused by sustained exposure to glucocorticoid medicines. Repeated or prolonged systemic treatment can impair bone formation and increase fracture risk.
Topical drug delivery : Administration of a medicine to a body surface for local or systemic absorption. Skin absorption affects betamethasone's local effect and the possibility of systemic exposure.
Show all 29